StackTerminal.Health

BETA

Nicotinamide Mononucleotide (NMN)

NAD+ precursor; early human trials suggest metabolic & energy benefits, especially in older adults.

dailyenergylongevitymetabolic

Evidence last reviewed: 04 Apr 2026

Evidence
1 record
1 recordBest grade:Moderate
Biomarkers
Insulin SensitivityMuscle Endurance

Current evidence shows NMN reliably raises NAD+ levels and may improve insulin sensitivity and muscle endurance in older adults. However, the long-term effects and safety in humans remain unclear, and more research is needed.

NAD+ levels / metabolic markers
Older adults; insulin-resistant individuals · RCTs (phase I/II)
Moderate

Reliably raises blood NAD+; some improvements in insulin sensitivity & muscle endurance in older adults.

Dose: 500 mgDuration: 8–12 weeks
Human trial data growing; long-term effects unknown.
Stacks containing Nicotinamide Mononucleotide (NMN)
Explore all →
No public stacks include this supplement yet.
Community Insights
Forms & usage
How to take it

Take 250-500 mg daily, preferably in the morning.

NMN powder / capsule
Sublingual may improve absorption.
Liposomal NMN
Claimed better bioavailability; limited comparative data.
Safety & trade-offs2
Note

May fuel pre-existing cancer cell growth in preclinical models (NAD+ supports cell proliferation) — human significance unclear

Note

FDA has raised exclusion concerns for NMN as a dietary supplement — regulatory status is legally ambiguous in the US

High  Moderate   Low / note

My notes
Sign in to keep a private note on Nicotinamide Mononucleotide (NMN).